Recruitment

Recruitment Status
Unknown status
Estimated Enrollment
30

Inclusion Criterias

Childhood acute lymphoblastic leukemia patients, age 0-18 years at diagnosis, treated at the department of pediatrics and adolescent medicine, Rigshospitalet.
Informed consent
Childhood acute lymphoblastic leukemia patients, age 0-18 years at diagnosis, treated at the department of pediatrics and adolescent medicine, Rigshospitalet.
Informed consent

Exclusion Criterias

None
None

Summary

Conditions
  • 6-mercaptopurine Therapy
  • Acute Lymphoblastic Leukemia
Type
Interventional
Phase
Phase 4
Design
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Younger than 18 years
Gender
Both males and females

Inclusion Criterias

Childhood acute lymphoblastic leukemia patients, age 0-18 years at diagnosis, treated at the department of pediatrics and adolescent medicine, Rigshospitalet.
Informed consent
Childhood acute lymphoblastic leukemia patients, age 0-18 years at diagnosis, treated at the department of pediatrics and adolescent medicine, Rigshospitalet.
Informed consent

Exclusion Criterias

None
None

Locations

Copenhagen, DK-, 2100
Copenhagen, DK-, 2100

Tracking Information

NCT #
NCT01906671
Collaborators
Danish Cancer Society
Investigators
  • Principal Investigator: Kjeld Schmiegelow, Professor Pediatric Clinic II, Rigshospitalet, Copenhagen
  • Kjeld Schmiegelow, Professor Pediatric Clinic II, Rigshospitalet, Copenhagen